View as Webpage

September 9, 2022

a6eae9b3-a027-43c5-b7d7-2f5971be3b18 image

Welcome to the latest edition of the BioLines Weekender...

As we approach the final quarter of the year and organizations are planning for 2023, talent is likely a part of the equation. Core to BioNJ's mission is to help companies find the quality candidates that they need to drive medical innovation forward.

BioNJ's Talent Services Career Portal was specifically designed to bring together top talent with leading companies in the New Jersey region. Featuring a state-of-the-art platform, both job seekers and hiring managers benefit from a sophisticated search engine as well as many user-friendly features. BioNJ's Talent Services Career Portal has quickly become THE place where life sciences applicants go to find their next job opportunity. Click here to take a look for yourself!

Planning a career change? Job seekers are invited to post your resumes for free. Similarly, BioNJ Member Companies that are searching for talent can post jobs at a discounted rate! Contact Peggy Schell at to learn more. 


Meanwhile, the BioNJ Team is busy planning for our fall calendar of events. We hope to see you at our upcoming in-person programs. Click here for the 2022 schedule. And, contact Cheri Hennessy at to learn about our many Sponsorship opportunities. 

Because Patients Can't Wait®,

The BioNJ Team

Upcoming BioNJ Events


BioNJ's Member Café

Register Today!

September 14, 2022

BioNJ's HR Conference

Register Today!

September 23, 2022

BioNJ's C-Suite Summit

Register Today!

October 18, 2022

BioNJ's IT/Cybersecurity Breakfast Briefing

Save the Date!

October 27, 2022

BioNJ's Inspiring Women in STEM Conference

Save the Date!

December 2, 2022

BioNJ's Patient Advocacy Summit

Attendance is exclusive to Patient Advocacy Groups and R&D company Patient advocacy and government affairs professionals.

Register Today!

December 13, 2022

Putting Patients First:

The Value of Medical Innovation


Consumers Frustrated With Health Insurance Coverage, Costs

Americans worry about insurance coverage costs and would like to see more solutions around transparency and out-of-pockets costs from health care institutions. That's according to a new PhRMA/Ipsos poll, which uncovered some frustrations over paying for and navigating the health care system. Many frustrations with health care hinge on inadequate health insurance coverage, the confusion with navigating insurance barriers to access and the unexpected expenses and coverage issues patients experience. Conducted among 2,510 American adults, the poll found a bipartisan supermajority (87%) of Americans feel politicians have lost touch with what the public needs from their health care. 

BioNJ in the News


WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey

BioNJ Member WuXi Biologics announced the release of its GMP Phase I drug substance clinical manufacturing facility, MFG18, in Cranbury, New Jersey. The site’s clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L, utilizing only single-use technology, adding to the Cranbury site’s full process development capability. “We congratulate WuXi Biologics for selecting Cranbury, New Jersey for its first GMP biomanufacturing site in North America and on achieving GMP release for that site,” said Debbie Hart, President and CEO of BioNJ. “We applaud the 150 New Jersey-based employees who made it possible. This is a great milestone for both WuXi Biologics and New Jersey as it brings significant clinical manufacturing capacity to the State’s booming life sciences cluster.”

NJ Company News


U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Princeton-based BioNJ Member Soligenix announced that the U.S. Food and Drug Administration (FDA) has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ (synthetic hypericin) for expanded treatment in patients with early stage CTCL. The grant, totaling $2.6 million over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the recently published positive Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in the treatment of early stage cutaneous T-cell lymphoma (CTCL). "We are pleased the FDA is supporting the HyBryte™ program and giving patients an opportunity to access the therapy in an open-label setting," stated Christopher J. Schaber, President and CEO of Soligenix, Inc.

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

Bridgewater-based BioNJ Member Amarin Corporation announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced ST-segment elevation myocardial infarction (STEMI), non-ST segment elevated myocardial infarction (NSTEMI), and other MI subtypes in patients with established cardiovascular disease (CVD) or diabetes with risk factors. The REDUCE-IT data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo. IPE also significantly reduced NSTEMI by 27%. The REDUCE-IT study randomized 8,179 adult statin-treated patients with elevated triglycerides and either established CV disease or diabetes plus risk factors to IPE or placebo; median follow-up was 4.9 years.

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

Bridgewater-based BioNJ Member Amarin Corporation announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis of REDUCE-IT, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total (first and subsequent) primary composite events (CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina) in current/former smokers by 23% and in former smokers by 29%, compared to patients who were assigned to placebo. IPE treatment reduced the incidence of CV events in current smokers by 23.8% and former smokers by 23.0% to levels observed in never smokers (25.7%) in the placebo group. 

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

Lawrenceville-based BioNJ Member Celsion Corporation provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. Additional data from its completed proof-of-concept mouse challenge study confirms that a PLACCINE vaccine can produce robust levels of IgG, neutralizing antibodies, and T-cell responses. The company previously reported evidence of IgG, neutralizing antibody and T-cell responses to its SARS-CoV-2 PLACCINE vaccines in normal mice. The additional data from its now completed mouse challenge study demonstrates the ability of the company’s PLACCINE vaccine to protect a SARS-CoV-2 mouse model in a live viral challenge. Dr. Corinne Le Goff, President and Chief Executive Officer of Celsion stated, “These results are very encouraging, and I believe that the versatility of our multicistronic formulated plasmid DNA platform could allow the development of new vaccines of the future, combining efficacy and convenience.”

Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East

BioNJ Member Helsinn Group, with a site in Iselin, and Juniper Biologics Pte Ltd, announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults. Chlormethine gel 0.016%, also known as mechlorethamine gel, is approved in multiple countries, including the EU and U.S., and is marketed under the trade names LEDAGA® and VALCHLOR®. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements.

Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Edison-based BioNJ Member, Hepion Pharmaceuticals, Inc., announced that it has screened the first subject in the ASCEND-NASH clinical trial. The trial is being conducted at up to 121 sites in seven countries, with 85 of the sites located within the U.S. ASCEND-NASH is a Phase 2b, randomized, multi-center, double-blinded study to evaluate the safety and efficacy of rencofilstat in 336 subjects dosed for 12 months. “Initiation of screening in our Phase 2b ASCEND-NASH clinical trial represents a significant step forward for our company,” stated Robert Foster, PharmD, Ph.D., Hepion’s Chief Executive Officer. “For quite some time, our team has been busy setting the stage for this major clinical trial. Our efforts have focused on ongoing optimization of drug manufacturing and product formulation; packaging; qualification of trial sites; and engagement with contract research organizations and regulatory agencies around the world.”

PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

South Plainfield-based BioNJ Member PTC Therapeutics, Inc. announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy. The STRIVE program provides grants to non-profit patient advocacy organizations serving the Duchenne community. This year, grants will fund projects focused on formal learning, psychological support, sexuality, and skills-based training for people with Duchenne. "We are proud to support the 2022 grant recipients for their work in the Duchenne community through our STRIVE Awards program. They have shown the broad range of needs in the Duchenne community, including programs supporting adults living with Duchenne," said Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics.

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

BioNJ Member Y-mAbs Therapeutics, Inc., with a site in Nutley, announced that the Israeli Ministry of Health has approved DANYELZA in Israel for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. In Israel, DANYELZA is expected to be commercialized by Takeda Israel, under the exclusive license and distribution agreement entered in 2020 between Takeda Israel and the company. Researchers at Memorial Sloan Kettering Cancer Center developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. 

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

BioNJ Member Y-mAbs Therapeutics, Inc., with a site in Nutley, announced that a meeting of the Oncologic Drugs Advisory Committee (“ODAC”) of the U.S. Food and Drug Administration (“FDA”) has been scheduled for October 28, 2022 to review the company’s Biological License Application (“BLA”) for its product candidate, OMBLASTYS® (omburtamab), an investigational radiolabeled antibody construct. Y-mAbs resubmitted the BLA for OMBLASTYS on March 31, 2022, and the FDA assigned a Prescription Drug User Fee Act goal date of November 30, 2022, for the completion of its priority review of the OMBLASTYS BLA. “We look forward to the October meeting with the Advisory Committee, as well as to continuing our dialogue with the FDA about OMBLASTYS and the important data, which we believe supports approval,“ said Thomas Gad, President, and Interim Chief Executive Officer.

Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials

New detailed results from BioNJ Member Eli Lilly and Company's Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment. Lebrikizumab, a high-affinity and potent IL-13 inhibitor, delivered similar results when dosed once every four weeks or once every two weeks after Week 16. The company previously announced topline results of these one-year analyses of ADvocate 1 and ADvocate 2 in June 2022. Efficacy with every four week dosing, after a 16-week induction period with lebrikizumab every two weeks, was similar to that of every two week dosing.

FDA Grants Priority Review to Efanesoctocog Alfa for People With Hemophilia A

Bridgewater-based BioNJ Member Sanofi announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A, a rare and life-threatening bleeding disorder. Sanofi and Sobi® collaborate on the development and commercialization of efanesoctocog alfa. The FDA grants priority review to therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. Efanesoctocog alfa received Breakthrough Therapy designation from the FDA and it is the first factor VIII therapy to receive this recognition. The FDA also granted efanesoctocog alfa Orphan Drug designation and Fast Track designation.

Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for up to Two Years in Children Aged 6 to 11 Years With Moderate-to-Severe Asthma

Bridgewater-based BioNJ Member Sanofi announced results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. The results are from data in children who entered the extension trial after finishing active treatment or placebo in the Phase 3 trial (pivotal trial). Children in the extension trial were treated for up to an additional year with Dupixent, providing up to two years of data in total. The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved respiratory indications. 

XenpozymeTM (olipudase alfa-rpcp) Approved by FDA as First Disease-Specific Treatment for ASMD (non-CNS manifestations)

Bridgewater-based BioNJ Member Sanofi announced the U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Xenpozyme is the first therapy indicated specifically for the treatment of ASMD and is currently the only approved treatment for this disease. Signs and symptoms of ASMD can present in infancy, childhood, or adulthood and may include enlarged spleen or liver, difficulty breathing, lung infections and unusual bruising or bleeding, among other disease manifestations. Until now, management of ASMD included supportive care to address the impact of individual symptoms and careful monitoring to detect potential disease complications.

Late-Breaking Results from Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

Princeton-based BioNJ Member Bristol Myers Squibb in collaboration with BioNJ Member Janssen Pharmaceutical Companies of Johnson & Johnson Inc., announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of the investigational oral factor XIa (FXIa) inhibitor, milvexian, which showed an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes and favorable safety profile in three arms compared to placebo when used in combination with background antiplatelet therapy in patients with an acute non-cardioembolic ischemic stroke or transient ischemic attack. The primary objective of this study was to detect a dose response for the composite endpoint of symptomatic ischemic stroke + MRI detected covert brain infarction across a 16-fold dose range; a dose response was not observed. 

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients With Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Titusville-based BioNJ Member the Janssen Pharmaceutical Companies of Johnson & Johnson announced the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. In the primary analysis (median follow-up of 13.5 months), the GRIFFIN study met its primary endpoint, resulting in a higher stringent complete response (sCR) rate for DARZALEX®-RVd compared with RVd alone by the end of post-autologous stem cell transplant (ASCT) consolidation therapy (42.4 percent vs. 32 percent; 1-sided P=0.0680) meeting the prespecified 1-sided alpha of 0.1.

Novartis Scemblix®, With Novel Mechanism of Action, Approved by the European Commission for Adult Patients With Chronic Myeloid Leukemia

East Hanover-based BioNJ Member Novartis announced that the European Commission (EC) has approved Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). Scemblix is the first CML treatment in Europe that works by specifically targeting the ABL myristoyl pocket (also known as a STAMP inhibitor in scientific literature), offering a reimagined treatment approach for patients who experience intolerance and/or resistance to currently available TKI therapies. It is estimated that, every year, more than 6,300 people will be diagnosed with CML in Europe. While many patients will benefit from available TKI therapies, a significant proportion may experience intolerance or resistance to these treatments.

Taiho Pharmaceutical Launches HSP90 Inhibitor Jeselhy® Tablets 40 mg (Pimitespib)

Taiho Pharmaceutical Co., Ltd., with a site in Princeton, announced that it has launched the oral heat shock protein (HSP) 90 inhibitor Jeselhy® tablets 40 mg (generic name: pimitespib). Jeselhy, a compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an antitumor effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR which are involved in the growth and survival of cancer. Based on the results of a Phase III trial (CHAPTER-GIST-301 trial) comparing the efficacy and safety of Jeselhy versus placebo in patients with previously treated gastrointestinal stromal tumor (GIST), Jeselhy received manufacturing and marketing approval in June for the indication of GIST that has progressed after chemotherapy.

Taiho Pharmaceutical Launches Solmack® Q-Arl S, a New Addition to the Solmack Line of Products for Skin Problems and Hangover Tiredness Associated with Malnutrition

Taiho Pharmaceutical Co., Ltd., with a site in Princeton, announced that it launched Solmack® Q-Arl S, a designated quasi-drug, in pharmacies and drugstores throughout Japan. Solmack Q-Arl S is effective for skin problems (rough skin, dry skin) and hangover tiredness associated with malnutrition in daily life. Since its launch in 1979, the Solmack series has been sold for more than 40 years to treat the nausea caused by overeating, overdrinking, hangovers, and other unpleasant aftereffects of drinking too much. Solmack Q-Arl S is the latest addition to the Solmack series, which contains L-cysteine and vitamins as active ingredients. L-cysteine supports alcohol metabolism which improves and prevents the tiredness associated with hangovers, while L-cysteine and vitamins improve and prevent skin problems (rough skin, dry skin), an effect different from that of conventional Solmack.

European Commission Grants Marketing Authorization for Ranivisio (ranibizumab), a Biosimilar to Lucentis, for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Parsippany-based BioNJ Member Teva Pharmaceutical Industries Ltd. announced that the European Commission (EC) has granted a Marketing Authorization for Ranivisio (ranibizumab), a biosimilar of the ophthalmology treatment Lucentis across all five indications in adults for which Lucentisis authorized. Ranivisiois licensed in adults to treat age-related macular degeneration (AMD) and four other ophthalmology indications: visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment resulting from diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR) and choroidal neovascularisation (CNV). Around 67 million people in Europe are affected by AMD. It is a leading cause of blindness for working age adults with uncontrolled diabetes, and the most common cause of blindness in developed countries. 

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

Parsippany-based BioNJ Member Teva Pharmaceutical Industries Ltd. announced that the first findings from the CONNECT clinical program on ProAir® Digihaler® (albuterol sulfate) inhalation powder with an integrated electronic module (eModule). The CONNECT1 trial was conducted to assess the role of the ProAir Digihaler System in the treatment of asthma. The ProAir Digihaler System is a digital health system that tracks reliever inhaler usage and inhalation quality as measured by inspiratory flow to aid in clinical decision-making. The Digihaler System is comprised of the ProAir digital inhaler, smart device application, Digital Health Platform cloud solution and dashboard to record and track usage. 

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

BioNJ Member Gilead Sciences, Inc., with a site in Morris Plainsannounced the positive overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meaningful improvement of 3.2 months in OS compared to TPC (median OS: 14.4 months vs. 11.2 months; hazard ratio [HR]=0.79; [95% confidence interval [CI]: 0.65-0.96]; p=0.02). OS was a key secondary endpoint of the trial.

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

BioNJ Member Pfizer, with a site in Peapack, announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. The FDA decision is informed by the interim analysis of a placebo-controlled Phase 2 study (NCT03765073), evaluating the safety and immunogenicity of GBS6 in healthy pregnant women aged 18 to 40 years, who were vaccinated during the second or early third trimester of pregnancy. The study remains ongoing, and Pfizer will publish outcomes from this clinical trial when it is completed.

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

BioNJ Member Pfizer, with a site in Peapack, announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) for individuals ages 12 years and older. An application for an Omicron-adapted bivalent vaccine for children 5 through 11 years of age is planned for submission to FDA in early October. The companies are working with the FDA to prepare an application for an Omicron-adapted bivalent vaccine in children 6 months through 4 years of age. The Omicron BA.4 and BA.5 subvariants together are the prevalent variants of concern in the U.S., prompting the FDA to instruct manufacturers to develop a variant-adapted vaccine that also addresses the spike protein of the Omicron BA.4/BA.5 subvariants.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

BioNJ Member Pfizer, with a site in Peapack, announced a 30-µg booster dose of their Omicron BA.1 Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals 12 years and older. The European Commission will review the CHMP recommendation and is expected to make a final decision soon. The Omicron BA.1-adapted bivalent vaccine contains 15 µg of mRNA encoding the wild-type spike protein of SARS-CoV-2, which is present in the Original Pfizer-BioNTech COVID-19 Vaccine, and 15 µg of mRNA encoding the spike protein of the Omicron BA.1 subvariant. Apart from the addition of the mRNA sequence of the BA.1 spike protein, all other components of the vaccine remain unchanged. 

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

BioNJ Member Pfizer, with a site in Peapack, announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. This application for a variation of the conditional marketing authorization (cMA) follows guidance from the EMA and International Coalition of Medicines Regulatory Authorities (ICMRA) to work towards introducing Omicron-adapted bivalent vaccines. The bivalent vaccine contains 15-µg of mRNA encoding the wild-type spike-protein of SARS-CoV-2, which is present in COMIRNATY® (the original Pfizer-BioNTech COVID-19 Vaccine) and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 variants. With the exception of the addition to the mRNA of the Omicron BA.4/BA.5 spike protein sequence, all other components of the vaccine remain unchanged. 

Merck ESG Initiatives Include $1B Sustainability Bond to Support Goals

Kenilworth-based BioNJ Member Merck & Co. announced the launch of its Sustainability Financing Framework to raise funds for ESG projects. Its inaugural $1 billion sustainability bond is aimed at supporting projects and partnerships in Merck’s four ESG priority areas: Access to Health, Employees, Environmental Sustainability and Ethics & Values. “For more than 130 years, our global team has pursued ESG excellence. Today, our ESG approach helps propel and enable our business strategy in ways that make us a better company — and a better corporate citizen. To that end, ESG underpins our Corporate Strategic Framework and every decision we make,” Merck CEO and President Robert Davis said. The ESG announcement also said that Merck will continue its membership in the Billion Dollar Roundtable, an industry organization that recognizes companies that achieve spending of at least $1 billion with minority-, women-, veteran-, LGBT- and disability-owned enterprises. 

Novo Nordisk to Acquire Forma Therapeutics and Expand Presence in Sickle Cell Disease and Rare Blood Disorders

Plainsboro-based BioNJ Member Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies, a group of disorders in which there is abnormal production or structure of the haemoglobin protein in the red blood cells.

New Data from Boehringer Ingelheim Support the Potential Use of Nintedanib in Children and Adolescents With Fibrosing Interstitial Lung Disease

Boehringer Ingelheim, with a site in North Brunswick, announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD). The trial showed encouraging data for both primary endpoints. The InPedILD results showed that the weight-based dosing regimen of nintedanib in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD. In addition, nintedanib had an acceptable safety and tolerability profile with no new safety signals observed when compared to adult patients with idiopathic pulmonary fibrosis (IPF), other progressive fibrosing interstitial lung disease (PF-ILD) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).

U.S. FDA Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults

Boehringer Ingelheim, with a site in North Brunswick, announced the U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab, marketed in the U.S. as SPEVIGO®, is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. The FDA’s approval of spesolimab is based on results from the pivotal EFFISAYIL® 1 Phase II clinical trial. In the 12-week trial, patients experiencing a GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a high, or very high, density of pustules, and impaired quality of life. 

Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III Champ Study Evaluating NVK002 for the Treatment of Myopia Progression in Children

Vyluma, Inc., with a site in Bridgewater, announced that the last patient visit has been completed for the primary analysis of the pivotal Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children. With this milestone, Vyluma remains on track for primary analysis readout later this year and regulatory submission in 2023. NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services and DNDi to Explore Joint Opportunities to Develop Affordable and Life-Saving New Drugs for Neglected Tropical Diseases

Princeton-based Dr. Reddy’s Laboratories Ltd and Aurigene Pharmaceutical Services Limited announced a Memorandum of Understanding with the Drugs for Neglected Diseases initiative (DNDi) and the DNDi India Foundation. The parties will explore a potential collaboration to develop and market novel and improved drugs for the treatment of identified Neglected Tropical Diseases (NTDs) of national and global importance. The parties will also seek to work towards ensuring access of those drugs at affordable prices to patients in need, particularly in low- and middle-income countries (LMICs) that are disproportionately affected by these NTDs. This potential partnership will aim to bring DNDi’s expertise in NTDs together with the scientific, technical and commercial capabilities of APSL and Dr. Reddy’s. 

Hikma Launches RYALTRIS™ Seasonal Allergic Rhinitis Nasal Spray in the U.S.

Hikma Pharmaceuticals, with a site in Berkeley Heights, and Glenmark Specialty S.A, with a site in Princeton, announced the launch of RYALTRIS™ (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. RYALTRIS™ is approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. RYALTRIS™ is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose. 

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Bridgewater-based Amneal Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD). CD/LD has been the gold standard of treatment for PD since the 1970s, but additional options are needed that can help patients function more consistently with an increase in “Good On” time per dose. Based on data in the Amneal clinical trials, IPX203 can offer patients additional “Good On” time with reduced dose frequency compared to immediate-release CD/LD. A post-hoc analysis of the Least Squares Mean difference at end of study (week 20) showed that IPX203 provided 1.55 more hours of “Good On” time per dose versus immediate-release CD/LD, representing a 70% per dose increase.

Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients With Hypoparathyroidism

Ascendis Pharma, with a site in Princeton, announced it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism. TransCon PTH has been granted Orphan designation in the United States and European Union. The NDA is based on data from the global Phase 3 PaTHway Trial and the Phase 2 PaTH Forward Trial, as well as data from the company’s ongoing open-label extension studies for both trials. Notably, 57 out of 59 patients continue in the open-label portion of the Phase 2 trial beyond two years of treatment, and 78 out of 79 patients continue in the open-label portion of the Phase 3 trial of TransCon PTH. 

Quizartinib Supplemental New Drug Application Submitted in Japan for Patients With Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia

Daiichi Sankyo, with a site in Basking Ridge, announced that it has submitted a

supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as continuation monotherapy for the treatment of adult patients in Japan with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). The sNDA is based on data from the QuANTUM-First Phase 3 trial. In QuANTUM-First, quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and continued as monotherapy following consolidation, demonstrated a statistically significant and clinically meaningful improvement in overall survival in adult patients with newly diagnosed FLT3-ITD positive AML compared to chemotherapy alone.

Daiichi Sankyo Announces Initiation of Phase 3 Trial of mRNA COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan

Daiichi Sankyo, with a site in Basking Ridge, announced that it has initiated a Phase 3

trial of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19), in healthy unvaccinated adults. The trial is an active-controlled, trial to investigate the non-inferiority of DS-5670 to an already-approved mRNA vaccine (Comirnaty®) in terms of immunogenicity and seroconversion rate1 in 322 healthy adults in Japan who have not yet received a COVID-19 vaccine or been infected with the novel coronavirus. DS-5670 is an mRNA vaccine against COVID-19 using a cationic lipid discovered by Daiichi Sankyo, designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus, and thus expected to have desirable efficacy and safety.

Bayer’s Kerendia Cuts Death in Diabetes, Chronic Kidney Disease

Whippany-based Bayer said the drug Kerendia has shown potential to significantly reduce sudden cardiac death among patients with chronic kidney disease and diabetes, a boost to its potential as a blockbuster medicine. Fresh data from a late-stage trial show the drug can reduce all cause of death, particularly heart disease, among people with chronic kidney disease and type 2 diabetes, regardless of the state of their kidney functioning. Kerendia is already approved for treating patients with chronic kidney disease in countries including the US, Europe, Japan and China. The drug company is pinning hopes on a newer generation of therapies, including Kerendia, to take over the sales momentum from products such as blood thinner Xarelto and eye treatment Eylea which will see cheaper competition in the coming years when patents expire. 

FDA Aurthorizes Quest Diagnostics' Proprietary Monkeypox Text for Emergency Use

Secaucus-based Quest Diagnostics on Thursday said it received U.S. Food & Drug Administration emergency use authorization for its lab-developed test specifically designed to detect monkeypox virus DNA. The EUA is the first granted to a commercially available monkeypox test in the U.S. “Quest is committed to developing high-quality diagnostic innovations to help respond to the monkeypox public health emergency,” Dr. Jay Wohlgemuth, Senior Vice President, Research & Development, Medical and Chief Medical Officer, Quest Diagnostics, stated. “With this FDA emergency authorization, Quest is positioned to complement the response of public health laboratories and help fight the spread of the virus.”

Funding/Economic Development

40c37e04-ab40-444c-88b5-63c2fc4d5e68 image

An Inside Look at the New Jersey Innovation Evergreen Fund Tax Credit Auction

The New Jersey Innovation Evergreen Fund (NJIEF) corporate tax credit auction is now open. The auction is an unprecedented opportunity for established corporate citizens in New Jersey to access a discount of up to 25% on their corporate business tax liability in the State and promote their strategic engagement and innovation objectives. Auction bids will be evaluated according to price and strategic commitment.


The funds raised from the auction will later be matched by professional venture capital firms and invested into high-growth, early stage start-up businesses across the Garden State. This novel platform is built to align important constituents operating in the State to create the conditions necessary to drive New Jersey towards the goal to become the most diverse, innovative ecosystem in the nation. 

BioNJ hosted a webinar, led by our colleagues at the New Jersey Economic Development Authority, which highlighted the structure of the program, the benefits to corporations, the process to apply and post-approval compliance requirements.

Click here to view a recorded version and learn what you need to know to take advantage of this game-changing opportunity to build New Jersey's innovation economy! 

People in the News


Tevogen Bio Appoints Global Safety Management Expert to Corporate Advisory Board

Warren-based BioNJ Member Tevogen Bio announced it appointed Victor Sordillo to its Corporate Advisory Board. Mr. Sordillo’s appointment contributes to the diversity of thought leadership within the company’s executive team by way of expertise in leadership, risk management and finance, as well as his previous roles on boards of various charitable organizations such as the American Red Cross and United Way. The late-stage clinical biotechnology company said Mr. Sordillo’s 35 years of experience in risk engineering will allow it to continue to pioneer the next era of medical innovation. Mr. Sordillo currently serves as an Executive Vice President at Sompo International, leading a global team of experienced risk control professionals that specializes in residential, commercial and industrial accounts.

Modern Meadow Promotes Roggero-Lovisi to CEO

Nutley-based biotech company Modern Meadow promoted Catherine Roggero-Lovisi to serve as its new Chief Executive Officer. Elevated from her role as President and Chief Operating Officer, Ms. Roggero-Lovisi succeeds Anna Bakst, who will continue to serve as Executive Chair on the company’s board of directors. In her new role, Ms. Roggero-Lovisi is responsible for furthering the company’s commercial development, enabling technology-focused partnerships and reaffirming its commitment to a global shift toward a more sustainable bioeconomy. Ms. Roggero-Lovisi has more than 20 years of executive experience, including in roles at L’Oréal, Revlon and Christian Louboutin. Modern Meadow’s proprietary technologies, including its Bio-Alloy and Bio-F@rm application platforms, offer alternatives to petrochemical and animal-derived materials and can be used by textiles, beauty and other industries.

Evolution of the Board of Directors

Bridgewater-based BioNJ Member Sanofi announced the appointment of Frédéric Oudéa as a Director and will be submitted for approval at the next Annual General Meeting. Following this Shareholders' Meeting, a proposal will be made to the Board of Directors of Sanofi to appoint Frédéric Oudéa as non-executive Chairman of the Board, replacing Serge Weinberg whose term of office will have expired. Frédéric Oudéa has announced that he will leave his position as CEO and Director of Société Générale in May 2023. Frédéric Oudéa is currently Chief Executive Officer of Société Générale, which he joined in 1996. At Société Générale, Frédéric Oudéa was successively Deputy Head and Head of the Corporate Banking arm in the United Kingdom, Head of Global Supervision and Development of the Equities Department, Group Deputy CFO in 2003 and then Group CFO in 2008, before becoming Chairman and CEO in 2009.

Novartis Appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., Steps Down from the Executive Committee of Novartis

East Hanover-based BioNJ Member Novartis announced that James E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31 after seven years leading research at Novartis. Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and Translational Medicine at Merck & Co., has been appointed as President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1, 2022, reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Marshall will become a member of the ECN. Vas Narasimhan said “I am deeply grateful to Jay for his invaluable contributions to reimagining how we discover innovative medicines, recruiting world-class scientific leaders and expanding our collaborations with leading biotech companies and academic institutions. 

Bridgewater Pharma Firm Appoints Former Sanofi Leader as EVP, Chief Commercial Officer

Bridgewater-based Amneal Pharmaceuticals said it appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer. Mr. Pesquin joins the company from Sanofi, where he served in leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America head for general medicines. Prior to that, Mr. Pesquin was the Global Head of the Diabetes and Cardiovascular Franchise. He also previously served as the Global Head of Sanofi’s Iberia and Latin America businesses. Before joining Sanofi, Mr. Pesquin held Regional Head, General Manager, Sales Head and Strategy Head roles at Abbott and Pfizer, Brand Management roles at Procter & Gamble and consultant roles with the Boston Consulting Group.

Photocure Appoints Anders Neijber, M.D., Ph.D., as Chief Medical Officer, Global Medical Affairs and Clinical Development

Photocure, with a site in Princeton, announced the appointment of Dr. Anders Neijber to the position of Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D. Dr. Neijber is Photocure's current Vice President, Medical Affairs and Clinical Development. He brings over 25 years of substantial experience in the Uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional leadership roles, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan, Ferring and Novartis. Dr. Neijber is a board-certified urologist and has held an Assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School.

BD Appoints Two Segment Presidents

Franklin Lakes-based BD (Becton, Dickinson and Company) announced the promotion of two executives to segment presidents. Michael Garrison has been named Executive Vice President and President of the Medical Segment. Richard Byrd has been named Executive Vice President and President of the Interventional Segment. Reporting to BD Chairman, CEO and President Tom Polen, Mr. Garrison and Mr. Byrd will be responsible for the global operational, commercial and financial performance of the businesses in their segments. “Mike and Rick are highly effective leaders who have demonstrated strategic and operational excellence in their nearly two decades at BD,” Mr. Polen said. “Their focus on driving growth and meaningful outcomes has been critical as we pursue our BD 2025 strategy.”

LEO Pharma Appoints Paul Navarre New Member of its Board of Directors

LEO Pharma, with a site in Madison, announced the appointment of Paul Navarre as a new member of its Board of Directors. Mr. Navarre currently serves as Chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holding, after ten years at Allergan, among other as President of International Operations (global except U.S.) and President of EAME (Europe, Middle East and Africa). Prior to that, he spent 15 years at Procter & Gamble managing multiple countries and global brands in pharmaceuticals and health and beauty care.



Merck Foundation Launches $20M Cancer Care Initiative

The Merck Foundation is sending a clear message: Cancer care should be equal for all. That’s why the Rahway-based Foundation launched a $20 million initiative toward that goal. The Alliance for Equity in Cancer Care is a five-year plan designed to help patients living in underserved communities receive timely access to high-quality, culturally responsive care. “The severity of the need to take action on advancing equity in cancer care cannot be overstated and will not be overlooked,” CEO Carmen Villar said. “We must move with urgency and work together to provide all people living with cancer access to high-quality care and treatment.” Through the initiative, the Foundation is awarding grants to health care nonprofits around the country – including RWJBarnabas Health right here in the Garden State – to develop programs that work toward advancing equity in cancer care.

Rowan University Welcomes Largest 1st-Year Class in Institution’s History

With fanfare and traditions, Rowan University welcomed its largest first-year class in the institution’s history this past weekend. Rowan joins other New Jersey-based schools touting the increase in enrollment. Montclair State University said it just had its largest incoming freshman class with 4,065 members in the Class of 2026 and Kean University said its fall enrollment was projected to be the highest in the school’s history with more than 2,000 students registered a week before classes were set to begin. In addition to the class of approximately 2,760 students that arrived amid Ali Houshmand’s 10th year as President, Rowan welcomed an estimated 2,000 transfer and international students, including attendees from 22 states and 14 countries (with the furthest, from the Philippines, traveling 8,559 miles).

Forbes College Rankings: Princeton, NJIT, Rutgers in Top 100

Forbes, which released its colleges rankings, said its list spotlights schools that offer an excellent education at a great price, graduate high-earners and propel students to become successful entrepreneurs and influential leaders in their fields. It’s editors also said it doesn’t give as much weight to prestige — noting that Harvard University did not make its Top 10. Princeton University, however, did. As usual, it was tops among New Jersey schools, coming in at No. 4. New Jersey Institute of Technology (No. 75) and Rutgers University–New Brunswick (No. 93) were the other New Jersey schools to crack the Top 100.

Forbes: 2 Schools in N.J. Among Top 10 for Highest-Earning Graduates

Degrees are nice. They’re just better when they come with a job — preferably one with a nice salary. Two schools in New Jersey ranked among the Top 10 for just that in the Forbes list of the 25 schools with the highest earners: Princeton University (#5) and Stevens Institute of Technology (#8).

New Chief of Blood Disorders Named to New Jersey's Only NCI-Designated Comprehensive Cancer Center

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, M.D., MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the State designated as a Comprehensive Cancer Center by the National Cancer Institute. In this role, he will oversee the Sections of Hematologic MalignanciesTransplant and Cell Therapy; and Benign Hematology. He also will serve as Professor of Medicine at Rutgers Robert Wood Johnson Medical School. He will join the cancer center in November. The selection comes following an extensive national search. Dr. Matasar comes from Memorial Sloan Kettering Cancer Center, where for the past 14 years, he has held numerous leadership positions including Section Head for Aggressive B-cell Lymphoma.

Why is CAR T-Cell Therapy So Exciting? Answers from an Expert

CAR T-cell immunotherapy is a treatment in which a patient's T-cells are genetically reprogrammed to find and kill cancer cells. Currently, CAR T-cell therapy products are used for patients with adult aggressive B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia in children or young adults who have already been through two standard treatments. When the Food and Drug Administration (FDA) approved this type of therapy, experts deemed it revolutionary, and a new era in the treatment of cancer. Ira Braunschweig, M.D., Chief of Transplant and Cell Therapy at Rutgers Cancer Institute of New Jersey, the state’s leading Cancer Center and only National Cancer Institute-Designated Comprehensive Cancer Center, Chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and Director of Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital, an RWJBarnabas facility, explains why this type of therapy is one of the most significant breakthroughs in cancer treatment.



SBIR/STTR Reauthorization Webinar

September 13, 2022

AdvaMed, BIO and CSBA is hosting a special briefing to discuss the success of SBIR/STTR programs, their economic impact and the important next steps to Federal reauthorization. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are highly competitive award-based programs that encourage domestic small businesses to engage in Federal Research/Research and Development with the potential for commercialization. Federal funding for the SBIR/STTR Program will expire on September 30, 2022, and we need your support to ensure timely reauthorization! Hear from successful SBIR/STTR grantees, program officers, and technical experts on these vital programs. After this webinar, you will be able to effectively advocate for Federal SBIR/STTR program reauthorization.

Understanding the Prescription Drug Provisions of the Inflation Reduction Act

September 21, 2022

On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, which includes a number of significant prescription drug-related provisions, including a new drug price negotiation program in Medicare, inflation rebates in Medicare Part B and Part D, and a redesign of the Medicare Part D benefit, with a new patient out-of-pocket cap of $2,000. Join BIO leadership as well as experts from the Hogan Lovells Life Sciences & Health Care team for overviews with Q&A on these newly enacted provisions..

Propelify Innovation Festival

October 6, 2022

For Those Who Propel Ideas Into Action! If you’re in the innovation community in the northeast you belong here. Learn from amazing speakers, connect with start-ups and investors, hire and be hired. Plus virtual reality, drones, music and a start-up competition. And lots more. BioNJ Members can attend for free. Register using code BioNJPropels.

ISG TechXchange: Healthcare & Life Sciences

October 13, 2022

The ISG TechXchange: Healthcare & Life Sciences will explore the evolving healthcare and life science ecosystems. Register today and embrace the digital transformation approaches organizations are taking to succeed in pushing the boundaries of innovation. Put interoperability at the heart of your organization. Utilize emerging innovations to rapidly respond to shifts in patient and payer expectations. Leverage the effects of pandemic-forced advancements to focus on innovation and diversification. Learn more and register here.

Genesis 2022

December 7, 2022

The annual Genesis conference has been a pillar of the life science sector for over two decades. Bringing together key opinion leaders, investors and innovators from across the sector to share insight, debate key trends and generate deals. Under a headline theme of “Maximizing Returns from Life Science Innovation”, we expect 2022 to be no different! 

Partner Spotlight

Email to connect you to this partner. 

For more information reach out to

Please contact BioNJ with any questions.  | 609-890-3185 |

Follow us on:

Facebook  Twitter  Instagram